Mounjaro Without Insurance: 7 Real Ways to Pay in 2026

What does Mounjaro actually cost without insurance right now?

Show up at a US pharmacy counter with a Mounjaro prescription and nothing to cover it, and you're looking at somewhere between $1,020 and $1,150 for a 28-day carton of four pens, no matter which dose your prescriber wrote. Costco and Walmart tend to sit at the lower end of that range; CVS and Walgreens tend to run higher. A GoodRx coupon barely moves the needle — recent pulls put the coupon price around $1,087 to $1,161 depending on the pharmacy, close to or occasionally above the plain cash rate rather than a meaningful discount.

That's the number that shows up in headlines, and it's real. It's also very likely not the number you'll actually end up paying, because it isn't the number anyone building a real budget around this drug should be anchoring to. The rest of this page is about the paths that get you below it.

Why won't insurance cover Mounjaro — even though it's a real, approved diabetes drug?

Mounjaro is FDA-approved, and it's approved for one thing: type 2 diabetes. Insurance formularies are built around approved indications, not around the drug itself. That means a plan can pay generously for Mounjaro when the diagnosis code on the claim is type 2 diabetes, and deny the identical prescription — same drug, same dose, same pharmacy — when the documented reason is weight management instead. If you were prescribed Mounjaro off-label for weight loss and got a denial, that isn't a mistake or an oversight on your insurer's part. It's how the system is built to work.

It's also worth knowing this isn't only a weight-loss problem. Even patients with a genuine type 2 diabetes diagnosis sometimes hit a prior-authorization requirement or a step-therapy rule that requires trying an older, cheaper diabetes drug first before Mounjaro gets approved. None of that changes the self-pay math on this page — it just means the cash-pay route can end up being the faster option even for someone technically eligible for coverage, while an appeal or a prior-auth request works its way through.

Where can you actually get Mounjaro without insurance? (Hint: it isn't sold self-pay under its own name)

Here's the detail that trips up almost everyone shopping this category: Eli Lilly does not run a self-pay vial or discount program for the Mounjaro brand itself. The company's direct-to-patient cash-pay program — the one that actually undercuts retail by more than half — exists only under the Zepbound name. Mounjaro and Zepbound are the same molecule, tirzepatide, made by the same manufacturer, at the same dose strengths. The only difference is the FDA approval attached to each brand: Mounjaro for type 2 diabetes, Zepbound for chronic weight management.

Because Zepbound carries the approval most cash-pay patients are actually using tirzepatide for, that's the brand Lilly built its self-pay infrastructure around. Through LillyDirect, self-pay Zepbound vials run $299 a month at the 2.5mg starting dose, $399 a month at 5mg, and a flat $449 a month from 7.5mg through 15mg — as long as your next order goes through within 45 days of your last delivery. Miss that window and the discounted price resets to a meaningfully higher published rate; the exact reset figure varies by dose and by source, so confirm the current number at LillyDirect before you count on it.

There's also a Mounjaro Savings Card, but it only helps if you're the reader this page isn't written for: it requires commercial insurance that already covers Mounjaro, dropping your copay to $25 a month, or commercial insurance that doesn't cover it, landing you at $499 a month. Both tiers require an active commercial plan to enroll — if your coverage was denied outright or you have none, the card isn't available to you. See the full Mounjaro Savings Card breakdown if you do have commercial insurance and want the details on which tier applies.

GoodRx and retail pharmacy cash price — how much do coupons really save?

Not much, and that's worth saying plainly before you spend time hunting for a magic coupon code. Lilly's pricing agreements with pharmacy benefit managers and discount-card programs limit how deep a third-party coupon can cut into Mounjaro's price. A GoodRx coupon commonly lands around $1,087 to $1,161 a month at a standard pharmacy — sometimes close to, or above, the pharmacy's own listed cash price, which is unusual for a discount card and a sign of how little room Lilly leaves for markdowns on this particular drug.

If you're going to shop retail cash prices, it's worth calling ahead or checking a live pricing tool by ZIP code, since chain-to-chain variation of $100 or more a month is real and worth capturing. But even at the best retail price you find, you're still paying roughly triple what LillyDirect's self-pay Zepbound program charges for the identical molecule — which is the comparison that actually matters here.

Compounded tirzepatide: the lower-cost, legally narrower alternative

During the years tirzepatide was in FDA-declared shortage, compounding pharmacies produced copies at scale, and prices as low as $199 to $249 a month flooded the market. That window is closed. The FDA first found the shortage resolved in October 2024; after a legal challenge from a compounders' trade group, the agency reconfirmed that finding on December 19, 2024. From there, 503A state-licensed pharmacies had until roughly mid-February 2025 and 503B outsourcing facilities until March 19, 2025 to stop producing bulk tirzepatide copies.

What survives in 2026 is narrower: a 503A pharmacy can still compound tirzepatide for one specific, named patient when a prescriber documents an actual clinical reason the commercial product can't meet — an allergy to an inactive ingredient, for instance. Cost savings alone isn't that justification under current FDA guidance, even though cost is the reason most patients land here. Eli Lilly has also sued several of the telehealth companies still operating in this space — Mochi Health, Henry Meds, Fella Health, and Willow Health Services were all named in suits filed in April 2025, alleging deceptive marketing of unapproved products. Those cases are still working through the courts as of mid-2026, which means the legal footing under any given compounding provider can shift.

Curex — the cheapest all-in compounded option

Curex currently prices compounded tirzepatide at roughly $199 a month all-in, covering the medication, the clinician consult, and shipping. That's the lowest verified all-in figure among the providers we checked. As with any compounded provider, that's a starter-dose rate — ask for the maintenance-dose price in writing before you enroll, since compounded pricing sometimes climbs as you titrate up and several competing programs quietly raise the price along the way.

Mochi Health — flat medication price, separate membership fee

Mochi Health advertises $199 a month for medication, but that headline number is incomplete. A separate $79-a-month membership is billed as its own auto-renewing subscription, so the real all-in cost is closer to $278 a month. The two charges don't cancel together, which shows up repeatedly in customer complaints about the billing structure. Mochi is also one of the companies Eli Lilly is currently suing over its compounding practices. Read the full Mochi Health review before enrolling.

Henry Meds — oral or injectable, no membership layer

Henry Meds prices compounded tirzepatide at $349 a month for the oral tablet and $449 a month for the injection, with no separate membership fee stacked on top. It's one of the few programs offering an oral option for women who'd rather skip needles. Like Mochi, Henry Meds was named in Eli Lilly's April 2025 lawsuits over compounded tirzepatide marketing. See the full Henry Meds review for the complete picture before you start.

Fridays is a fourth option worth knowing about, even though it isn't in the table above: it runs $240 a month on a 12-month prepay plan or $359 a month month-to-month, and bundles in dietitian coaching. Read the Fridays review if wraparound support matters as much to you as the medication price.

Ranked: the cheapest legitimate ways to pay for Mounjaro with zero coverage

• Lilly Cares Foundation — free, if you qualify. Only for uninsured patients with a documented type 2 diabetes diagnosis and income under roughly 400% of the federal poverty level. Worth checking first if you have T2D, before shopping any paid option below.
• Curex, compounded — ~$199/mo. The lowest all-in paid price we verified, medication and consult included, at a starter dose.
• Fridays, compounded, annual plan — $240/mo. Requires a 12-month prepay commitment to hit this rate.
• Mochi Health, compounded — ~$278/mo all-in. $199 medication plus a $79 membership billed separately.
• LillyDirect Zepbound self-pay, 2.5mg — $299/mo. The floor for brand-name, FDA-approved tirzepatide, sold under Zepbound rather than Mounjaro.
• Henry Meds, compounded oral — $349/mo. No membership fee; oral tablet option.
• LillyDirect Zepbound self-pay, 7.5mg–15mg, or Henry Meds injection — $449/mo. Flat rate across the higher brand-name dose tiers, or the injectable compounded option.
• GoodRx coupon or retail cash price, no program — ~$1,020–$1,161/mo. The ceiling almost nobody in this situation should end up paying.

Can you get insurance to cover it anyway? Appeals, prior auth, and the diagnosis-code gap

A denial isn't necessarily the end of the road, and it's worth understanding why the denial happened before deciding whether to fight it. Coverage decisions run off the diagnosis code your provider submits with the claim — type 2 diabetes (ICD-10 code E11) and obesity (E66) sit in entirely different coverage lanes on most formularies, even for the exact same drug. If you genuinely have type 2 diabetes and your prescription was coded as weight management by mistake, the fix can be as simple as your provider resubmitting with the correct diagnosis code attached.

If the denial is accurate — your plan genuinely excludes Mounjaro for your situation — most insurers still allow an appeal within a defined window after the denial letter, typically somewhere between 30 and 180 days depending on the plan. Appeals that succeed tend to include real documentation: comorbidities, prior treatment history, and a clear clinical rationale from your prescriber, not just a request to reconsider. It's worth asking your provider's office directly whether an appeal is realistic for your specific denial before assuming the door is closed, and worth asking whether a step-therapy requirement — trying a cheaper diabetes drug first — is what's actually standing between you and coverage rather than a flat exclusion.

Patient assistance: can you get Mounjaro free?

Eli Lilly runs Lilly Cares Foundation, a charitable patient-assistance program that can provide Mounjaro at no cost — but the eligibility bar is specific, and it doesn't apply to everyone reading this page. You need an active Mounjaro prescription written for type 2 diabetes, no current insurance coverage for the drug, and household income at or below roughly 400% of the federal poverty level — sources put that figure somewhere between about $62,600 and $63,840 a year for a single person in 2026, so confirm the exact current threshold at lillycares.com rather than treating either number as fixed.

One thing to be clear-eyed about: Lilly Cares' free-drug program is built around the Mounjaro brand and its diabetes indication, not Zepbound and weight management. If your prescription is written for weight loss rather than type 2 diabetes, this program is very unlikely to be your path — the LillyDirect self-pay or compounded routes above are the more realistic ones for that situation. Processing time reported for approved applications ranges from about one to four weeks depending on how complete your documentation is when you apply.

What a full year of Mounjaro without insurance actually costs

• Retail, no program: ~$12,240–$13,800/year ($1,020–$1,150 x 12)
• GoodRx coupon: ~$13,044–$13,932/year ($1,087–$1,161 x 12)
• LillyDirect Zepbound, starting dose (2.5mg): ~$3,588/year ($299 x 12)
• LillyDirect Zepbound, maintenance (7.5–15mg): ~$5,388/year ($449 x 12)
• Curex compounded: ~$2,388/year ($199 x 12)
• Mochi Health compounded, all-in: ~$3,336/year ($278 x 12)
• Henry Meds compounded, oral: ~$4,188/year ($349 x 12)
• Henry Meds compounded, injection: ~$5,388/year ($449 x 12)
• Lilly Cares Foundation, if eligible: $0/year

Laid out this way, the gap between the cheapest legitimate path and full retail runs past $11,000 a year — and almost none of that gap comes down to which pharmacy has the friendliest coupon. It comes down to whether you know the Mounjaro brand has no self-pay program of its own, and shop Zepbound or a vetted compounded provider instead.

Red flags when buying tirzepatide online without insurance

Demand for cheap tirzepatide has attracted real fraud, not just aggressive marketing, so a few things are worth watching for regardless of which path you choose.

• Walk away from any seller that doesn't require an actual prescription or clinician evaluation — that isn't legal, and it's a real counterfeit and dosing-error risk.
• Watch for 'tirzepatide sodium' or 'tirzepatide acetate' on a label or product page — the FDA has warned these salt forms are different active ingredients from FDA-approved tirzepatide, not proven safe or effective, with no lawful basis identified for their use in compounding.
• Be cautious of any compounder that won't name the specific state-licensed pharmacy actually filling your prescription if you ask directly.
• Treat pricing dramatically below every figure on this page — with no explanation for how it's possible — as a sign you're not looking at a legitimate product.
• If a compounded provider markets cost savings as the clinical justification for compounding rather than an individual medical reason, that's the opposite of what the current FDA pathway actually requires.